WASHINGTON, DC (October 28, 2026) – Today, the Biotechnology Innovation Organization (BIO) and the Council of State Bioscience Associations (CSBA) released new national and state-level data on the U.S. bioscience industry’s economic impact.The report, “The U.S. Bioscience Economy: Advancing Innovation and Strengthening States and Regions,” examines the industry’s economic footprint through employment, wages, business establishments, university research and development, access to capital, and other measures.From 2021 through 2025, the U.S. bioscience industry had a significant, broad-based economic footprint and impact on the nation’s economy. The industry in 2025:Generated $3.19 trillion in total economic output.Directly employed 2.31 million people, a 7% increase from 2021.Operated more than 156,000 business establishments, a 22% increase from 2021.Supported 9.67 million direct, indirect, and induced jobs when considering the industry’s broader economic impacts.Increased employment in 41 states, the District of Columbia, and Puerto Rico.“America’s bioscience industry continues to create jobs, fuel economic growth, and deliver life-saving medicines to patients. The United States must continue promoting an environment that supports scientific discovery and strengthens our leadership in biotechnology. This report makes clear that we cannot take that strength for granted. Now is the time to invest in America's biotech ecosystem, advance policies that foster innovation and lay the groundwork for America’s long-term leadership for years to come. The public policies enacted today at the national and state level will directly impact whether American biotech continues to thrive here at home and where the next generation of breakthroughs will be developed,” said John F. Crowley, president and CEO of BIO.“This report series has tracked the U.S. bioscience industry’s growth and its role in state and regional economies for more than two decades. The latest findings…
Read More